Horan J D, Johnson J D
Can Med Assoc J. 1978 Aug 26;119(4):334-8.
In an 8-week double-blind study of the clinical effectiveness of flunisolide, a new synthetic corticosteroid intended for topical use, 73 persons with perennial rhinitis received 300 microgram/d of either flunisolide or placebo. The flunisolide group showed a significantly greater reduction than the placebo group in the daily duration of sneezing, stuffy nose, nose blowing and postnasal drip, but not of runny nose, and a significantly greater reuction in the severity of all these manifestations. Substantial or total control of manifestations was reported by 73% of the flunisolide group and 25% of the placebo group, a significant difference. Careful monitoring of the plasma cortisol concentration revealed no evidence of adrenal suppression, and in no patient did the value fall below normal. The lack of adrenal suppression may be due to the very small amount of corticosteroid administered and the rapid metabolism of flunisolide into a relatively inactive metabolite.
在一项为期8周的关于氟尼缩松（一种新的用于局部用药的合成皮质类固醇）临床疗效的双盲研究中，73名常年性鼻炎患者每日接受300微克的氟尼缩松或安慰剂治疗。与安慰剂组相比，氟尼缩松组在打喷嚏、鼻塞、擤鼻涕和鼻后滴漏的每日持续时间上有显著更大幅度的减少，但在流鼻涕方面没有，并且在所有这些症状的严重程度上也有显著更大幅度的减轻。氟尼缩松组73%的患者和安慰剂组25%的患者报告症状得到了实质性或完全控制，差异显著。对血浆皮质醇浓度的仔细监测未发现肾上腺抑制的证据，且没有患者的值低于正常水平。未出现肾上腺抑制可能是由于给予的皮质类固醇量非常少以及氟尼缩松快速代谢为相对无活性的代谢产物。
